Beclobrate (CAS 55937-99-0) Suppliers and Product Information

Beclobrate is a hypolipidemic agent structurally related to clofibrate. It is reportedly useful in types IIa-V hyperlipoproteinemias, promoting normalization of the atherogenic index. Beclobrate was introduced into medicine in 1985 as an antihyperlipidaemic agent. However, its marketing authorization has been withdrawn due to potential hepatic toxicity concerns and the availability of safer therapeutic alternatives.

Beclobrate is also known by synonyms such as Beclipur, Ethyl 2-[2-(α-(4-chlorophenyl)-4-tolyloxy)-2-methylbutyrate], Sgd 24774, and Turec. It functions as an antihyperlipidemic agent.

Frequently Asked Questions about Beclobrate

Q: What is the primary use of Beclobrate?

A: Beclobrate is primarily used as an antihyperlipidaemic agent, designed to help lower lipid levels in the blood.

Q: Is Beclobrate still available for medical use?

A: No, Beclobrate's marketing authorization has been withdrawn due to potential hepatic toxicity concerns and the availability of safer therapeutic alternatives.

Q: What is the recommended storage condition for Beclobrate?

A: Beclobrate should be stored at a temperature between 2-8°C.

Q: What is the toxicity level of Beclobrate?

A: The LD50 (lethal dose for 50% of the test population) for Beclobrate when administered orally in mice is 8000 mg/kg.